FAKTOR YANG BERHUBUNGAN DENGAN KEJADIAN EFEK SAMPING TERAPI EGFR-TKI PADA PASIEN KANKER PARU NON-SEL KECIL: SCOPING REVIEW

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard therapy for EGFR-mutated non-small cell lung cancer (NSCLC), yet adverse events vary across patients. This scoping review aimed to map the associated factors related to the occurrence and Common Terminology Criteria for Adverse Events (CTCAE) grade of EGFR-TKI adverse events in NSCLC patients and to describe the biological and pharmacological mechanisms that may explain these associations. Following PRISMA-ScR and Joanna Briggs Institute (JBI) guidance with the Population, Concept, Context (PCC) framework, searches across PubMed, Scopus, and Web of Science (2016–2026) identified 412 records. After removing 118 duplicates, 294 records underwent independent dual screening, 68 full texts were assessed, and 14 primary studies were included and appraised using JBI checklists. Four categories of associated factors emerged. First, ABCB1 (1236C>T, 2677G>T/A), ABCG2 (421C>A), and CYP2D6 polymorphisms were associated with slower drug clearance (erlotinib CL/F reduced by 29.4%), diarrhea (87.5% vs. 36.4%; p = 0.002), CTCAE grade 2–3 rash, and hepatic dysfunction. Second, baseline serum albumin ≤ 3.0 g/dL was independently associated with CTCAE grade 4–5 interstitial lung disease (ILD) (aOR = 3.91; 95% CI 1.20–12.71), presumably via a hypothesized increase in unbound drug fraction, whereas body weight < 40 kg was associated with CTCAE grade ≥ 3 diarrhea (aOR = 7.93; 95% CI 2.32–27.10). Third, a 30 mg vs. 40 mg/day afatinib starting dose was associated with fewer CTCAE grade 3 adverse events (7% vs. 24%; p < 0.0001), and dose reduction lowered diarrhea, rash, and paronychia severity without compromising progression-free survival (HR = 0.86; 95% CI 0.58–1.29). Fourth, older age (≥ 60–65 years; aOR = 2.32), female sex (aOR = 2.04), BMI ≥ 25 kg/m² on gefitinib (aOR = 4.571), and concomitant medications/polypharmacy were associated with organ toxicities. In conclusion, pre-treatment risk evaluation, CTCAE grade monitoring, and dose reduction may be considered in accordance with official guidelines and product labeling, as the mapped evidence is predominantly observational and associative.

Authors

Institutions

Publication Details

Journal
Journal of Health and Nursing.
Published
2026-11-19
DOI
https://doi.org/10.58738/jhn.v4i2.2016
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

FAKTOR YANG BERHUBUNGAN DENGAN KEJADIAN EFEK SAMPING TERAPI EGFR-TKI PADA PASIEN KANKER PARU NON-SEL KECIL: SCOPING REVIEW

Mally Ghinan Sholih, Rahmawati Azara Putri, Eca Enjiska
Journal of Health and Nursing.
Lung Cancer Treatments and Mutations
article

FAKTOR YANG BERHUBUNGAN DENGAN KEJADIAN EFEK SAMPING TERAPI EGFR-TKI PADA PASIEN KANKER PARU NON-SEL KECIL: SCOPING REVIEW

Mally Ghinan Sholih, Rahmawati Azara Putri, Eca Enjiska
article en

Abstract

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard therapy for EGFR-mutated non-small cell lung cancer (NSCLC), yet adverse events vary across patients. This scoping review aimed to map the associated factors related to the occurrence and Common Terminology Criteria for Adverse Events (CTCAE) grade of EGFR-TKI adverse events in NSCLC patients and to describe the biological and pharmacological mechanisms that may explain these associations. Following PRISMA-ScR and Joanna Briggs Institute (JBI) guidance with the Population, Concept, Context (PCC) framework, searches across PubMed, Scopus, and Web of Science (2016–2026) identified 412 records. After removing 118 duplicates, 294 records underwent independent dual screening, 68 full texts were assessed, and 14 primary studies were included and appraised using JBI checklists. Four categories of associated factors emerged. First, ABCB1 (1236C>T, 2677G>T/A), ABCG2 (421C>A), and CYP2D6 polymorphisms were associated with slower drug clearance (erlotinib CL/F reduced by 29.4%), diarrhea (87.5% vs. 36.4%; p = 0.002), CTCAE grade 2–3 rash, and hepatic dysfunction. Second, baseline serum albumin ≤ 3.0 g/dL was independently associated with CTCAE grade 4–5 interstitial lung disease (ILD) (aOR = 3.91; 95% CI 1.20–12.71), presumably via a hypothesized increase in unbound drug fraction, whereas body weight < 40 kg was associated with CTCAE grade ≥ 3 diarrhea (aOR = 7.93; 95% CI 2.32–27.10). Third, a 30 mg vs. 40 mg/day afatinib starting dose was associated with fewer CTCAE grade 3 adverse events (7% vs. 24%; p < 0.0001), and dose reduction lowered diarrhea, rash, and paronychia severity without compromising progression-free survival (HR = 0.86; 95% CI 0.58–1.29). Fourth, older age (≥ 60–65 years; aOR = 2.32), female sex (aOR = 2.04), BMI ≥ 25 kg/m² on gefitinib (aOR = 4.571), and concomitant medications/polypharmacy were associated with organ toxicities. In conclusion, pre-treatment risk evaluation, CTCAE grade monitoring, and dose reduction may be considered in accordance with official guidelines and product labeling, as the mapped evidence is predominantly observational and associative.

Journal of Health and Nursing.Vol. 4(2)
University of Singaperbangsa Karawang (ID)
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon